Wesley Medical Research partnered with the University of Sydney in Australia for Tourette Syndrome Treatment Market

 

Increasing drug approval by regulatory authorities is projected to foster the growth of the Tourette syndrome treatment market. For instance, in October 2017, Neurocrine Biosciences Inc. announced that the Food Drug and Administration approved valbenazine orphan drug designation to treat pediatric patients with Tourette syndrome. Also, a growing partnership among key players for developing new treatments is again augmenting the growth of the market. For instance, in September 2017, Teva Pharmaceutical Industries and Nuvelution Pharma announced their partnership to develop AUSTEDO (deutetrabenazine) tablets for the treatment of tics which is associated with tourette syndrome in pediatric patients in the U.S. This partnership will drive the development of Austedo (deutetrabenazine) in Tourette syndrome by bringing new treatment options more quickly which are more necessary for the affected young patients.

North America is expected to dominate the Tourette Syndrome Treatment Market owing to the presence of a large number of key players such as AstraZeneca PLC, Otsuka Holdings Co., Ltd, and Catalyst Pharmaceutical Parteners, Inc. According to the National Institute Of Neurological Disorders And Stroke(NIH), it is estimated that around 2,00,000 Americans have the most severe form of Tourette syndrome and as many as one in 100 shows milder or fewer complex symptoms such as vocal tics.

In March 2019, Wesley Medical Research partnered with the University of Sydney in Australia which carried the clinical trial to investigate whether medical cannabis could be used to treat individuals with Tourette syndrome. This trial will help examine the efficacy and safety of cannabinoids on tic frequency as well as the psychiatric symptoms associated with Tourette syndrome.

In August 2019, Emalex Biosciences, Inc. (Emalex), announced that it has received Fast Track designation for its investigational product, ecopipam, from the U.S. Food and Drug Administration (FDA) for the treatment of patients with Tourette Syndrome (TS).

Tourette syndrome (TDS), otherwise known as vocal nodules, is composed of the symptoms and signs of Tourette syndrome, which are repetitive and rapid speech patterns, tics, and other unique characteristics which can be different in each individual. The most common sign of Tourette syndrome is tics, which are unexpected, repetitive, jaw-dropping, or yelp-like sounds that some individuals make. A person with Tourette disorder has multiple vocal tics and at times even has multiple motor tics. The person can also have problems with balance and gait and tend to twirl, jig, and skip. Treatments include muscle relaxation exercises, speech therapy, neurofeedback, biofeedback, vitamin and mineral supplementation, psychotherapy, and sometimes medication.